Altimmune Inc. (ALT) shares took a beating Wednesday, falling over 17% after the company announced it's selling $75 million worth of stock to raise cash for its late-stage drug trials. It's the classic biotech funding dilemma: you need money to develop promising drugs, but diluting shareholders rarely goes over well in the short term.

The Deal Behind the Drop

Here's what happened. Altimmune struck a securities purchase agreement with a new institutional investor to sell 17,045,454 shares of common stock (or pre-funded warrants if the buyer prefers). The offering was priced at approximately $4.40 per share, which represents a discount to where the stock was trading before the announcement.

The company expects to pull in about $75 million in gross proceeds before accounting for placement agent fees and other expenses that come with raising money. The deal is set to close around January 29, assuming all the standard conditions are met.

So where's the money going? Altimmune plans to use the funds to prepare for its upcoming Phase 3 trial in MASH (metabolic dysfunction-associated steatohepatitis), a serious liver disease. The rest will go toward working capital and general corporate purposes. The star of the show here is pemvidutide, Altimmune's dual glucagon/GLP-1 agonist that the company is developing for obesity, metabolic diseases, and liver conditions.

What the Charts Are Saying

Technical analysis paints an interesting picture. Despite Wednesday's decline, Altimmune stock is still trading 17.4% above its 20-day simple moving average and 19.8% above its 100-day SMA. That suggests the stock had built up some momentum before this offering news hit.

But here's the catch: the RSI sits at 78.59, firmly in overbought territory. Meanwhile, the MACD is above its signal line, indicating bullish momentum. This combination is a bit contradictory—the stock has been performing well, but it may be due for a correction. Key resistance to watch is at the $6 level.

Over the past year, shares are down roughly 26.33% and are trading much closer to their 52-week lows than highs.

Why This Funding Matters

Altimmune is a clinical-stage biopharmaceutical company betting big on pemvidutide (formerly ALT-801), an investigational peptide-based GLP-1/glucagon dual receptor agonist. The drug is currently being studied for both obesity and MASH, conditions that represent massive market opportunities if the trials succeed.

This stock offering is significant because it provides the runway Altimmune needs to advance pemvidutide into Phase 3 trials. For a clinical-stage biotech, securing funding is always a delicate balance—you need capital to progress, but equity offerings dilute existing shareholders. Investors are now watching to see whether the company's drug development progress can justify the dilution and drive the stock higher over time.

ALT Price Action: Altimmune shares closed Wednesday down 17.15% at $5.12.